IJSTR

International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
0.2
2019CiteScore
 
10th percentile
Powered by  Scopus
Scopus coverage:
Nov 2018 to May 2020

CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT

IJSTR >> Volume 8 - Issue 10, October 2019 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Analytical Method Development Report For The Determination Of Assay & Related Substances Of Ibutilide Fumarate In Ibutilide Fumarate Injection

[Full Text]

 

AUTHOR(S)

Aakisetti Siva Sankar, Dr. G. Srinivasarao

 

KEYWORDS

Ibutilide fumarate, HPLC, API manufactures’s method, Stress testing

 

ABSTRACT

The aim of the study is to develop an effective assay to quantify ibutilide fumarate and its related substances in ibutilide fumarate injection. Initially, the API manufacturer’s method was followed which involves two different UV-HPLC assays for both ibutilide fumarate and its related impurities. Upon considering the heat degradation results of the API method, specificity and stability of the known impurities (related substances) was not clearly determined. So the API method was modifiedby using low-pressure gradient UV-HPLCfor accurate detection of ibutilide and its related impurities. The inference of the drug, under various physio-chemical conditions like acid stress, base stress, heat stress, dark and light exposed, peroxide treated, dry heat are also studied. Chromatogram results of the developed method observed to be highly stable and sensitivity as it is able to clearly differentiate the excipient, related impurities and degradation product. Therefore the developed method can be used for the determination of assay and related substances of Ibutilide fumarate in Ibutilide Fumarate injection.

 

REFERENCES

[1] Cimini, M. G., Brunden, M. N., & Gibson, J. K. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. European journal of pharmacology, 222(1), 93-98 (1992).
[2] Labhasetwar, V., Underwood, T., Heil, J. R., Gallagher, M., Langberg, J., & Levy, R. J.Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. Journal of cardiovascular pharmacology, 24(5), 826-840 (1994).
[3] Soucier, R., Silverman, D., Abordo, M., Jaagosild, P., Abiose, A., Madhusoodanan, K. P.,&Berns, E.. Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study). Medical Science Monitor, 9(3), PI19-PI23 (2003).
[4] Bernard, E. O., Schmid, E. R., Schmidlin, D., Scharf, C., Candinas, R., &Germann, R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Critical care medicine, 31(4), 1031-1034 (2003).
[5] Ellenbogen, K. A., Clemo, H. F., Stambler, B. S., Wood, M. A., &VanderLugt, J. T. Efficacy of ibutilide for termination of atrial fibrillation and flutter. The American journal of cardiology, 78(8), 42-45 (1996).
[6] Naccarelli, G. V., Lee, K. S., Gibson, J. K., &VanderLugt, J. Electrophysiology and pharmacology of ibutilide. The American journal of cardiology, 78(8), 12-16 (1996).
[7] Antonicelli, R., Testarmata, P., &Recanatini, A. Ibutilide in rapid conversion of atrial flutter in octogenarians. Drugs & aging, 19(10), 787-791 (2002).
[8] Franczyk, B., Gluba-Brzózka, A., Banach, M., &Rysz, J. The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. Current vascular pharmacology, 14(3), 260-265 (2016).
[9] Li, Y., Tian, L., Huang, Y., & Hua, L. Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy Chinese men. Clinical therapeutics, 29(9), 1957-1966 (2007).
[10] Gowda, R. M., Punukollu, G., Khan, I. A., Wilbur, S. L., Vasavada, B. C., &Sacchi, T. J.Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. American journal of therapeutics, 10(4), 259-263 (2003).
[11] Steinwender, C., Hönig, S., Kypta, A., Kammler, J., Schmitt, B., Leisch, F., & Hofmann, R. Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter. International journal of cardiology, 141(3), 260-265 (2010).
[12] Hohnloser, S. H., Dorian, P., Straub, M., Beckmann, K., &Kowey, P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. Journal of the American College of Cardiology, 44(1), 99-104 (2004).
[13] Tian, L., Li, Y., Huang, Y., Kuang, F., Li, F., & Hua, L. Sensitive method for the determination of ibutilide in human plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B, 816(1-2), 81-85 (2005).
[14] LIU, X. H., LI, H., & WANG, M. L. HPLC determination of the content and the related substances of ibutilide fumarate for injection [J]. Chinese Journal of Pharmaceutical Analysis, 8, 035 (2009).
[15] Hsu, C. L., & Walters, R. R. Chiral separation of ibutilide enantiomers by derivatization with 1-naphthyl isocyanate and high-performance liquid chromatography on a Pirkle column. Journal of Chromatography A, 550, 621-628 (1991).
[16] Chang-yuan, L. H., & Walters, R. R. Assay of the enantiomers of ibutilide and artilide using solid-phase extraction, derivatization, and achiral-chiral column-switching high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 667(1), 115-128 (1995).
[17] Labhasetwar, V., Strickberger, S. A., Underwood, T., Davis, J., & Levy, R. J. Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode. Journal of cardiovascular pharmacology, 31(3), 449-455 (1998).
[18] LI, G. L., & LI, M. Preparation and quality control of ibutilide fumarate for injection [J]. Chinese Journal of New Drugs, 3, 016 (2007).
[19] Buist, S. C., Hsu, C. Y. L., & Walters, R. R. Sensitive determination of a new antiarrhythmic agent, trecetilide, in plasma by high-performance liquid chromatography with fluorescence detection1. Journal of Chromatography A, 828(1-2), 259-265 (1998).
[20] Perricone, S. C., Chidester, C. G., & Hester, J. B. Synthesis of (R)-N-[4-[4-(dibutylamino)-1-hydroxybutyl] phenyl] methanesulfonamide,(E)-2-butenedioate (2: 1) salt (artilide fumarate) and the enantiomers of N-[4-[4-(ethylheptylamino)-1-hydroxybutyl] phenyl] methanesulfonamide,(E)-2-butenedioate (2: 1) salt (ibutilide fumarate). Tetrahedron: Asymmetry, 7(3), 677-690 (1996).
[21] Buchanan, L. V., Thompson, D. D., Hsu, C. Y. L., Walters, R. R., & Gibson, J. K. Antiarrhythmic and electrophysiologic effects of sublingual ibutilide fumarate. Drug development research, 34(4), 322-328 (1995).
[22] Mansouri, Z. U.S. Patent No. 9,707,177. Washington, DC: U.S. Patent and Trademark Office (2017).
[23] Dorsey, J. G., Cooper, W. T., Siles, B. A., Foley, J. P., & Barth, H. G. Liquid chromatography: Theory and methodology. Analytical Chemistry, 68(12), 515-568 (1996).
[24] Sengupta, S., Zhao, G., Capila, I., Eavarone, D., &Sasisekharan, R. U.S. Patent Application No. 11/495,947 (2007).